Speciality: Hematology
Description:
A warm welcome to all the medical professionals in this memorable scientific session on the management of venous thromboembolism in patients of general surgery.
Venous thromboembolism is the most common cause of death observed in surgical patients. The risk of venous thromboembolism (VTE) among the population of postoperative patients is heterogeneous and depends on intrinsic patient factors.
The risk is determined by the combination of different factors and features such as the use of prophylaxis, perioperative care, etc which are related to the type of surgery. It is evident that extended use of prophylaxis, early mobilization, and the implication of improved perioperative care can help in reducing the risk of VTE in surgical patients.
Thus, depending on the risk for VTE and major bleeding in surgical patients combined methods of mechanical and pharmacological prophylaxis or only mechanical prophylaxis may be preferred.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor
2.
Sickle Cell Disease Drug Pulled From Global Markets
3.
A US health panel advises starting mammograms at age 40 rather than 50.
4.
'Converging' Evidence of Link Between Air Pollution and Breast Cancer
5.
Getting More Done With Less Blood.
1.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
2.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
Unlocking the Potential of Palbociclib: A Comprehensive Overview
5.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation